# Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure

> **NCT02352285** · PHASE4 · TERMINATED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Heart Failure With Hyponatremia

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02352285
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352285, "Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02352285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*